TrialThe oncologist2023

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.

Jennifer K Litton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.